EA
FOLD

Emerald Advisers’s Amicus Therapeutics FOLD Stock Holding History

Emerald Advisers’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-572,520
Closed -$8.94M – 263
2018
Q2 		$8.94M Buy
+572,520
New +$8.65M 0.34% 109
2016
Q4 		– Sell
-1,354,790
Closed -$10M – 283
2016
Q3 		$10M Buy
1,354,790
+298,207
+28% +$2.01M 0.45% 85
2016
Q2 		$5.77M Sell
1,056,583
-841,238
-44% -$5.88M 0.28% 118
2016
Q1 		$16M Buy
1,897,821
+163,255
+9% +$1.16M 0.78% 40
2015
Q4 		$16.8M Buy
1,734,566
+583,336
+51% +$5.26M 0.79% 34
2015
Q3 		$16.1M Buy
1,151,230
+51,600
+5% +$809K 0.84% 28
2015
Q2 		$15.6M Buy
1,099,630
+397,321
+57% +$4.78M 0.74% 42
2015
Q1 		$7.49M Buy
+702,309
New +$6.19M 0.38% 87

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Emerald Advisers's FOLD Position: Q3 2018 in Review

Emerald Advisers sold out of Amicus Therapeutics (FOLD) in Q3 2018, closing a stake of 572,520 shares — an estimated $8.94M sold.

Emerald Advisers first reported a position in FOLD in Q1 2015 and held it in 8 quarters. The position peaked at $16.8M in Q4 2015. 204 funds tracked by Wall St. Rank hold FOLD as of Q3 2018.

  • Emerald Advisers reported no remaining Amicus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Emerald Advisers sold 572,520 Amicus Therapeutics shares in Q3 2018, an estimated $8.94M.
  • Emerald Advisers first reported a position in Amicus Therapeutics in Q1 2015 and held it in 8 quarters.
  • Emerald Advisers's Amicus Therapeutics position peaked at $16.8M in Q4 2015.
  • 204 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2018.

Based on Emerald Advisers's 13F filing for Q3 2018, filed 31 Oct 2018.